Skip to main content
Erschienen in: Familial Cancer 4/2009

01.12.2009

Molecular study of CEPBA in familial hematological malignancies

verfasst von: R. El Abed, V. Bourdon, L. Huiart, F. Eisinger, A. Khelif, M. Frenay, P. Gesta, L. Demange, H. Dreyfus, V. Bonadona, C. Dugast, H. Zattara, L. Faivre, T. Noguchi, R. Sauvan, Z. Soua, H. Sobol

Erschienen in: Familial Cancer | Ausgabe 4/2009

Einloggen, um Zugang zu erhalten

Abstract

Familial aggregation in patients with several haematological malignancies has been described, but the genetic basis for this familial clustering is not known. Few genes predisposing to familial haematological malignancies have been identified, among which RUNX1 and CEBPA have been described as predisposing genes to acute myeloid leukemia (AML). Recent studies on RUNX1 suggest that germline mutations in this gene predispose to a larger panel of familial haematological malignancies than AML. In order to strengthen this hypothesis, we have screened CEBPA for germline mutations in several families presenting aggregation of hematological malignancies (including chronic or acute, lymphoid or myeloid leukemias, Hodgkin’s or non Hodgkin’s lymphomas, and myeloproliferative or myelodysplastic syndromes) with or without solid tumours. Although no deleterious mutations were found, we report two novel and rare variants of uncertain significance. In addition, we confirm that the in frame insertion c.1175_1180dup (p.P194_H195dup) is a germline polymorphism.
Literatur
1.
Zurück zum Zitat Fuchs O (2007) Growth-inhibiting activity of transcription factor C/EBPalpha, its role in haematopoiesis and its tumour suppressor or oncogenic properties in leukaemias. Folia Biol (Praha) 53(3):97–108 Fuchs O (2007) Growth-inhibiting activity of transcription factor C/EBPalpha, its role in haematopoiesis and its tumour suppressor or oncogenic properties in leukaemias. Folia Biol (Praha) 53(3):97–108
2.
Zurück zum Zitat Frohling S, Schlenk RF, Stolze I et al (2004) CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol 22(4):624–633CrossRefPubMed Frohling S, Schlenk RF, Stolze I et al (2004) CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol 22(4):624–633CrossRefPubMed
3.
Zurück zum Zitat Zhang DE, Zhang P, Wang ND, Hetherington CJ, Darlington GJ, Tenen DG (1997) Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice. Proc Natl Acad Sci USA 94(2):569–574CrossRefPubMed Zhang DE, Zhang P, Wang ND, Hetherington CJ, Darlington GJ, Tenen DG (1997) Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice. Proc Natl Acad Sci USA 94(2):569–574CrossRefPubMed
4.
Zurück zum Zitat Wouters BJ, Lowenberg B, Erpelinck-Verschueren CA, van Putten WL, Valk PJ, Delwel R (2009) Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood 113(13):3088–3091CrossRefPubMed Wouters BJ, Lowenberg B, Erpelinck-Verschueren CA, van Putten WL, Valk PJ, Delwel R (2009) Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood 113(13):3088–3091CrossRefPubMed
5.
Zurück zum Zitat Fuchs O, Provaznikova D, Kocova M et al (2008) CEBPA polymorphisms and mutations in patients with acute myeloid leukemia, myelodysplastic syndrome, multiple myeloma and non-Hodgkin’s lymphoma. Blood Cells Mol Dis 40(3):401–405CrossRefPubMed Fuchs O, Provaznikova D, Kocova M et al (2008) CEBPA polymorphisms and mutations in patients with acute myeloid leukemia, myelodysplastic syndrome, multiple myeloma and non-Hodgkin’s lymphoma. Blood Cells Mol Dis 40(3):401–405CrossRefPubMed
6.
Zurück zum Zitat Smith ML, Cavenagh JD, Lister TA, Fitzgibbon J (2004) Mutation of CEBPA in familial acute myeloid leukemia. N Engl J Med 351(23):2403–2407CrossRefPubMed Smith ML, Cavenagh JD, Lister TA, Fitzgibbon J (2004) Mutation of CEBPA in familial acute myeloid leukemia. N Engl J Med 351(23):2403–2407CrossRefPubMed
7.
Zurück zum Zitat Nanri T, Uike N, Kawakita T et al (2006) A pedigree harboring a germ-line N-terminal C/EBP{alpha} mutation and development of acute myeloblastic leukemia with a somatic C-terminal C/EBP{alpha} mutation. Blood 108(11):1916 Nanri T, Uike N, Kawakita T et al (2006) A pedigree harboring a germ-line N-terminal C/EBP{alpha} mutation and development of acute myeloblastic leukemia with a somatic C-terminal C/EBP{alpha} mutation. Blood 108(11):1916
8.
Zurück zum Zitat Pabst T, Eyholzer M, Haefliger S, Schardt J, Mueller BU (2008) Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia. J Clin Oncol 26(31):5088–5093CrossRefPubMed Pabst T, Eyholzer M, Haefliger S, Schardt J, Mueller BU (2008) Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia. J Clin Oncol 26(31):5088–5093CrossRefPubMed
9.
Zurück zum Zitat Sellick GS, Spendlove HE, Catovsky D, Pritchard-Jones K, Houlston RS (2005) Further evidence that germline CEBPA mutations cause dominant inheritance of acute myeloid leukaemia. Leukemia 19(7):1276–1278CrossRefPubMed Sellick GS, Spendlove HE, Catovsky D, Pritchard-Jones K, Houlston RS (2005) Further evidence that germline CEBPA mutations cause dominant inheritance of acute myeloid leukaemia. Leukemia 19(7):1276–1278CrossRefPubMed
10.
Zurück zum Zitat Renneville A, Mialou V, Philippe N et al (2009) Another pedigree with familial acute myeloid leukemia and germline CEBPA mutation. Leukemia 23(4):804–806CrossRefPubMed Renneville A, Mialou V, Philippe N et al (2009) Another pedigree with familial acute myeloid leukemia and germline CEBPA mutation. Leukemia 23(4):804–806CrossRefPubMed
11.
Zurück zum Zitat Preudhomme C, Renneville A, Bourdon V et al (2009) High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder. Blood 113(22):5583–5587CrossRefPubMed Preudhomme C, Renneville A, Bourdon V et al (2009) High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder. Blood 113(22):5583–5587CrossRefPubMed
12.
Zurück zum Zitat Lin LI, Chen CY, Lin DT et al (2005) Characterization of CEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells. Clin Cancer Res 11(4):1372–1379CrossRefPubMed Lin LI, Chen CY, Lin DT et al (2005) Characterization of CEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells. Clin Cancer Res 11(4):1372–1379CrossRefPubMed
13.
Zurück zum Zitat Biggio V, Renneville A, Nibourel O et al (2008) Recurrent in-frame insertion in C/EBPalpha TAD2 region is a polymorphism without prognostic value in AML. Leukemia 22(3):655–657CrossRefPubMed Biggio V, Renneville A, Nibourel O et al (2008) Recurrent in-frame insertion in C/EBPalpha TAD2 region is a polymorphism without prognostic value in AML. Leukemia 22(3):655–657CrossRefPubMed
14.
Zurück zum Zitat Resende C, Regalo G, Duraes C, Carneiro F, Machado JC (2007) Genetic changes of CEBPA in cancer: mutations or polymorphisms? J Clin Oncol 25(17):2493–2494 (author reply 4–5)CrossRefPubMed Resende C, Regalo G, Duraes C, Carneiro F, Machado JC (2007) Genetic changes of CEBPA in cancer: mutations or polymorphisms? J Clin Oncol 25(17):2493–2494 (author reply 4–5)CrossRefPubMed
15.
Zurück zum Zitat Wouters BJ, Louwers I, Valk PJ, Lowenberg B, Delwel R (2007) A recurrent in-frame insertion in a CEBPA transactivation domain is a polymorphism rather than a mutation that does not affect gene expression profiling-based clustering of AML. Blood 109(1):389–390CrossRefPubMed Wouters BJ, Louwers I, Valk PJ, Lowenberg B, Delwel R (2007) A recurrent in-frame insertion in a CEBPA transactivation domain is a polymorphism rather than a mutation that does not affect gene expression profiling-based clustering of AML. Blood 109(1):389–390CrossRefPubMed
16.
Zurück zum Zitat Fröhling S, Corbacioglu A, Schlenk R, Döhner H, Döhner K (2007) In reply. J Clin Oncol 25(17):2494–2495CrossRef Fröhling S, Corbacioglu A, Schlenk R, Döhner H, Döhner K (2007) In reply. J Clin Oncol 25(17):2494–2495CrossRef
Metadaten
Titel
Molecular study of CEPBA in familial hematological malignancies
verfasst von
R. El Abed
V. Bourdon
L. Huiart
F. Eisinger
A. Khelif
M. Frenay
P. Gesta
L. Demange
H. Dreyfus
V. Bonadona
C. Dugast
H. Zattara
L. Faivre
T. Noguchi
R. Sauvan
Z. Soua
H. Sobol
Publikationsdatum
01.12.2009
Verlag
Springer Netherlands
Erschienen in
Familial Cancer / Ausgabe 4/2009
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-009-9289-x

Weitere Artikel der Ausgabe 4/2009

Familial Cancer 4/2009 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.